Tenaya Therapeutics Announces New Appointments to Leadership Team Portfolio News / By Karina Tin June 30, 2021
Carmot to receive royalty payments upon sales of Amgen’s FDA approved first-in-class KRAS G12C Inhibitor, LUMAKRAS™ (sotorasib); Further demonstrates the value of Carmot’s therapeutic platform Portfolio News / By Karina Tin June 29, 2021
Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer Portfolio News / By Karina Tin June 28, 2021
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor Portfolio News / By Karina Tin June 28, 2021
Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes and Showcases its Technology at the Upcoming American Diabetes Association Scientific Session Portfolio News / By Karina Tin June 24, 2021
Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders Portfolio News / By Karina Tin June 22, 2021
Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development Portfolio News / By Karina Tin June 21, 2021
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin June 18, 2021
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications Portfolio News / By Karina Tin June 17, 2021
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI) Portfolio News / By Karina Tin June 16, 2021